Roche has no rights to Sovaldi, panel rules

Share this article:

An arbitration panel has ruled that Roche neither holds any patent claims to Gilead HCV drug Sovaldi nor is it entitled to any damages or other relief, Gilead stated in a regulatory filing this past Friday. Roche began the arbitration in 2013, claiming that its 2004 collaboration with Pharmasset—the firm Gilead bought in 2012 and the original owner of Sovaldi—netted the drugmaker a piece of the exclusive rights.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters